HIV/AIDS News

Post-exposure prophylaxis for HIV remained significantly underutilized, especially in acute care settings, according to study results published in Open Forum Infectious Diseases.

Long-acting injectable PrEP is feasible and acceptable to both men and women, according to a study presented at the AIDS 2024 meeting in Munich.

A seventh person has potentially been cured of HIV after receiving a stem cell transplant to treat blood cancer, researchers announced on the eve of the 25th International AIDS Conference.

Only about half of gay or bisexual men received recommended sexually transmitted infection testing at their initial visit to a private, outpatient facility, researchers reported.

Patients with HIV who undergo immediate antiretroviral therapy may not experience significant differences in chronic kidney disease outcomes compared with patients who defer treatment.

Patients receiving infectious diseases consultation over the past decade were increasingly complex, generally sicker and more likely to die soon after a consultation was performed.

SAN ANTONIO — We caught up with Connie Steed, MSN, RN, CIC, FAPIC, at the annual meeting of the Association for Professionals in Infection Control and Epidemiology to find out how she got “Hooked on ID.”

Lenacapavir, an injectable antiretroviral drug approved by the FDA for HIV treatment, prevented 100% of new HIV infections among women in a phase 3 trial in Africa, demonstrating its efficacy as PrEP, Gilead Sciences said.

We checked in with CDC Director Mandy K. Cohen, MD, MPH, for an update on the agency’s efforts to modernize the nation’s disease surveillance and data systems and improve how the CDC communicates with the public and physicians.

The CDC has published guidance recommending that providers counsel certain patients on the harms and benefits of doxycycline for post-exposure prophylaxis — or doxy-PEP — for the prevention of sexually transmitted infections.